Novo says Ozempic shows lower risk of cardiovascular events than Lilly's Mounjaro
NVO•Novo Nordisk said a real-world study found adults with type 2 diabetes who increased Ozempic to 2 mg had a statistically significant 6% lower risk of major cardiovascular events than those who switched to Mounjaro doses of up to 15 mg.
1. Study findings
The analysis covered 636,525 adults and was presented at the European Association for the Study of Diabetes annual meeting in Milan. Within 365 days of their first prescription, 67.2% remained on Ozempic 1 mg, while 29.2% increased to Ozempic 2 mg or switched to Mounjaro.
2. Treatment patterns
At the 720-day follow-up, 57.4% had stayed on Ozempic 1 mg, 36.9% had increased to 2 mg and 5.7% had switched to Mounjaro. Novo executive medical director Michael Radin said the real-world findings may offer insight into how treatment intensification affects cardiovascular outcomes.
3. Earlier analysis
The findings build on an earlier analysis of the same data that examined HbA1c, a measure of blood-glucose levels over time, and weight loss. Novo and Lilly are competing for dominance in the U.S. obesity drug market, which analysts expect to reach $100 billion to $150 billion by 2030.
